Sarepta Therapeutics CEO Chris Garabedian Resigns

Sarepta Therapeutics said Chief Executive Chris Garabedian resigned, following tension between the biotech and the U.S. Food and Drug Administration over a key muscular dystrophy drug. Chief marketing officer Edward Kaye will take over as interim CEO.



from WSJ.com: US Business http://ift.tt/1C7Klhq

via IFTTT